UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

  • Guggenheim Securities Healthcare Innovation Conference (fireside chat): Tuesday, November 12 at 9:30 a.m. ET

  • Stifel 2024 Healthcare Conference (fireside chat): Monday, November 18 at 3:00 p.m. ET

The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.

About Merus

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus' website, X and LinkedIn.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.

CONTACT: Investor and Media Inquiries:

Sherri Spear

Merus N.V.

SVP Investor Relations and Strategic Communications

617-821-3246

[email protected]

Kathleen Farren

Merus N.V.

Assoc. Director IR/Corp Comms

617-230-4165

[email protected]